Novel role of the nutraceutical bioactive compound berberine in lectin-like OxLDL receptor 1-mediated endothelial dysfunction in comparison to lovastatin

Nutr Metab Cardiovasc Dis. 2017 Jun;27(6):552-563. doi: 10.1016/j.numecd.2017.04.002. Epub 2017 Apr 19.

Abstract

Background and aims: Oxidized LDL (oxLDL) or pro-inflammatory stimuli lead to increased oxidative stress linked to endothelial dysfunction and atherosclerosis. The oxLDL receptor-1 (LOX1) is elevated within atheromas and cholesterol-lowering statins inhibit LOX1 expression. Berberine (BBR), an alkaloid extracted from plants of gender Berberis, has lipid-lowering and anti-inflammatory activity. However, its role in regulating LOX1-mediated signaling is still unknown. The aim of this study was to investigate the effect of BBR on oxLDL- and TNFα-induced endothelial dysfunction in human umbilical vein endothelial cells (HUVECs) and to compare it with that of lovastatin (LOVA).

Methods and results: Cytotoxicity was determined by lactate dehydrogenase assay. Antioxidant capacity was measured with chemiluminescent and fluorescent method and intracellular ROS levels through a fluorescent dye. Gene and protein expression levels were assayed by qRT-PCR and western blot, respectively. HUVECs exposure to oxLDL (30 μg/ml) or TNFα (10 ng/ml) for 24 h led to a significant increase in LOX1 expression, effect abrogated by BBR (5 μM) and LOVA (5 μM). BBR but not LOVA treatment abolished the TNFα-induced cytotoxicity and restored the activation of Akt signaling. In spite of a low direct antioxidant capacity, both compounds reduced intracellular ROS levels generated by treatment of TNFα but only BBR inhibited NOX2 expression, MAPK/Erk1/2 signaling and subsequent NF-κB target genes VCAM and ICAM expression, induced by TNFα.

Conclusions: These findings demonstrated for the first time that BBR could prevent the oxLDL and TNFα - induced LOX1 expression and oxidative stress, key events that lead to NOX, MAPK/Erk1/2 and NF-κB activation linked to endothelial dysfunction.

Chemical compounds studied in this article: Berberine (PubChem CID: 2353); Lovastatin (PubChem CID: 53232).

Keywords: Berberine; Endothelial dysfunction; Lovastatin; Reactive oxygen species; Tumor necrosis factor α; oxLDL; oxLDL receptor-1.

Publication types

  • Comparative Study

MeSH terms

  • Anti-Inflammatory Agents / pharmacology*
  • Antioxidants / pharmacology*
  • Berberine / pharmacology*
  • Cell Survival / drug effects
  • Cells, Cultured
  • Cytoprotection
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Human Umbilical Vein Endothelial Cells / drug effects*
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Human Umbilical Vein Endothelial Cells / pathology
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Lipoproteins, LDL / pharmacology*
  • Lovastatin / pharmacology*
  • Membrane Glycoproteins / metabolism
  • NADPH Oxidase 2
  • NADPH Oxidases / metabolism
  • NF-kappa B / metabolism
  • Nitric Oxide Synthase Type III / metabolism
  • Oxidative Stress / drug effects
  • Reactive Oxygen Species / metabolism
  • Scavenger Receptors, Class E / agonists*
  • Scavenger Receptors, Class E / metabolism
  • Signal Transduction / drug effects
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Anti-Inflammatory Agents
  • Antioxidants
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipoproteins, LDL
  • Membrane Glycoproteins
  • NF-kappa B
  • OLR1 protein, human
  • Reactive Oxygen Species
  • Scavenger Receptors, Class E
  • Tumor Necrosis Factor-alpha
  • oxidized low density lipoprotein
  • Berberine
  • Lovastatin
  • NOS3 protein, human
  • Nitric Oxide Synthase Type III
  • CYBB protein, human
  • NADPH Oxidase 2
  • NADPH Oxidases
  • Extracellular Signal-Regulated MAP Kinases